/PRNewswire/ Oblique Therapeutics AB (publ.), a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs,.
GOTHENBURG, Sweden, Nov. 9, 2022 /PRNewswire/ Oblique Therapeutics AB (publ.), a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs
Gothenburg, Sweden,9 November 2022 – Oblique Therapeutics AB (publ.), a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs, is pleased to announce the confirmation of Christer Nordstedt MD.PhD. as Chief Executive Officer (CEO). Christer Nordstedt will assume the position on 1st December 2022.
/PRNewswire/ Press release - New Patent granted Oblique Therapeutics AB today announces that key aspects of its AbiProt® technology for discovering and.